Inhaled corticosteroids and bone density

In a 2-year double-blind study in 103 male and female asthma patients 18 to 50 years of age previously maintained on bronchodilator therapy (Baseline FEV 1 85%-88% predicted), treatment with mometasone furoate dry powder inhaler 200 mcg twice daily resulted in significant reductions in lumbar spine (LS) BMD at the end of the treatment period compared to placebo. The mean change from Baseline to Endpoint in the lumbar spine BMD was - (-%) for the mometasone furoate dry powder inhaler group compared to (%) for the placebo group. In another 2-year double-blind study in 87 male and female asthma patients 18 to 50 years of age previously maintained on bronchodilator therapy (Baseline FEV 1 82%-83% predicted), treatment with mometasone furoate dry powder inhaler 400 mcg twice daily demonstrated no statistically significant changes in lumbar spine BMD at the end of the treatment period compared to placebo. The mean change from Baseline to Endpoint in the lumbar spine BMD was - (-%) for the mometasone furoate group compared to - (-%) for the placebo group.

Inhaled corticosteroids and bone density

inhaled corticosteroids and bone density

Media:

inhaled corticosteroids and bone densityinhaled corticosteroids and bone densityinhaled corticosteroids and bone densityinhaled corticosteroids and bone densityinhaled corticosteroids and bone density